June 29, 2026 — 11 days remain. If you purchased metformin from Teva, Granules (Avet), or Heritage Pharmaceuticals between July 20, 2015 and June 2, 2020, you have until July 10, 2026 to file a claim in a $5.55 million class action settlement — no documentation required. Simultaneously, a separate and far more significant litigation track is quietly building for metformin users who developed cancer. This article breaks down both tracks, explains who qualifies for each, and tells you exactly what to do before the deadline passes.
The $5.55M Metformin Class Action Settlement: What You Need to Know Before July 10
The metformin lawsuit captioned In re Metformin Marketing and Sales Practices Litigation, filed in the U.S. District Court for the District of New Jersey, has reached a combined settlement of $5.55 million. Teva Pharmaceuticals is contributing $3 million, while Granules India (marketed under the Avet label) and Heritage Pharmaceuticals are jointly contributing $2.55 million. The settlement also resolves related claims against CVS Pharmacy for its role in selling these products to consumers.
This settlement addresses false-advertising and NDMA contamination claims — meaning defendants allegedly sold metformin products without disclosing that the drugs contained levels of the probable carcinogen N-nitrosodimethylamine (NDMA). Critically, this settlement does NOT cover personal injury or wrongful death claims. If you developed cancer you believe is linked to metformin NDMA exposure, your claim must be pursued on a completely separate legal track, discussed below.
Who Qualifies to File a Claim
You are likely a class member if you meet all three of the following criteria:
- You are a U.S. resident
- You purchased or paid for a metformin-containing drug manufactured or sold by Teva, Granules/Avet, or Heritage Pharmaceuticals (including purchases through CVS)
- Your purchase occurred between July 20, 2015 and June 2, 2020
Individual consumers are not required to submit documentation to file a claim. Payment will be distributed on a pro-rata basis among all valid claimants, meaning the more people who file, the smaller each individual share. Filing sooner rather than later does not increase your share, but missing the July 10, 2026 deadline means forfeiting your right to any payment entirely.
Key Dates and the Opt-Out Decision
The opt-out deadline is also July 10, 2026 — the same date as the claim filing deadline. This is a critical distinction: if you remain in the settlement class, you permanently release all false-advertising and contamination-related claims against the settling defendants. The court’s fairness hearing is scheduled for August 12, 2026, at which point the settlement will be reviewed for final approval. If you wish to preserve your right to sue Teva, Granules, or Heritage independently — for example, as part of a personal injury claim — you must opt out before July 10. You cannot file a class action claim and opt out simultaneously.
The NDMA Science: Why This Contamination Matters
NDMA (N-nitrosodimethylamine) is classified as a probable human carcinogen by the U.S. Food and Drug Administration, as well as the EPA, WHO, and the International Agency for Research on Cancer (IARC). The FDA’s acceptable daily intake (ADI) limit for NDMA is 96 nanograms per day — a threshold several recalled metformin extended-release (ER) products were confirmed to exceed following testing in 2020.
The contamination issue in the metformin lawsuit was first flagged by online pharmacy Valisure, which detected NDMA in metformin ER products in early 2020. The FDA confirmed the findings and recalls followed in waves from 2020 through 2022, involving manufacturers including Apotex, Amneal, Teva, Marksans, Lupin, Nostrum, Sun Pharma, and Viona Pharmaceuticals. One important scientific boundary: FDA testing confirmed NDMA contamination only in extended-release (ER) formulations. Immediate-release metformin was not implicated in any recall and is not part of this litigation.
Cancers Associated With NDMA Exposure
Plaintiffs in the personal injury track of the metformin lawsuit are asserting NDMA exposure caused or contributed to a range of diagnosed cancers. The cancers most frequently cited in NDMA-related litigation include:
- Liver cancer (hepatocellular carcinoma)
- Colorectal cancer
- Stomach (gastric) cancer
- Bladder cancer
- Kidney cancer
- Esophageal cancer
Attorneys currently building personal injury metformin lawsuits are paying particular attention to liver failure, transplant cases, and wrongful death claims, which represent the highest-value tier of potential compensation. If a family member died from a cancer potentially linked to metformin NDMA exposure, a wrongful death calculator can provide an early-stage estimate of potential damages before formal legal consultation.
Metformin Lawsuit Data Snapshot: Recalls, Manufacturers, and Litigation Status
| Data Point | Detail | Source |
|---|---|---|
| Class action settlement total | $5.55 million (Teva $3M; Granules/Heritage $2.55M) | D.N.J. Court Records, 2026 |
| Claim/opt-out deadline | July 10, 2026 | Settlement Administrator, 2026 |
| Fairness hearing | August 12, 2026 | D.N.J. Court Calendar, 2026 |
| NDMA acceptable daily intake (FDA) | 96 nanograms/day | FDA.gov |
| Formulations affected | Extended-release (ER) only — immediate-release not recalled | FDA.gov |
| Recall wave manufacturers | Apotex, Amneal, Teva, Marksans, Lupin, Nostrum, Sun Pharma, Viona | FDA Recall Database, 2020–2022 |
| Estimated personal injury tiers | $10,000–$500,000+ (varies by cancer type, duration, exposure) | Analogous NDMA litigation benchmarks, 2026 |
| U.S. metformin users in surveillance data | 5.4 million (FDA Sentinel active surveillance) | CDC.gov |
| MDL consolidation status (mid-2026) | No certified federal MDL yet; consolidation discussions active | Federal court filings, 2026 |
| Cancers linked to NDMA | Liver, colorectal, stomach, bladder, kidney, esophageal | IARC/FDA classifications |
The Personal Injury Track: Cancer Victims and MDL Consolidation
The consumer class action settlement is only half of the metformin lawsuit landscape in 2026. For individuals who developed one of the NDMA-linked cancers listed above, a separate personal injury litigation track is actively building momentum — and the compensation potential is dramatically higher than any pro-rata share of a $5.55 million fund.
As of mid-2026, there is no certified federal multidistrict litigation (MDL) for metformin personal injury cases, but consolidation discussions are ongoing and cases are accumulating in federal courts. Legal analysts frequently draw comparisons to the Zantac (ranitidine) NDMA litigation that began building in 2020 and 2021. However, there is a pivotal evidentiary distinction favoring metformin plaintiffs: the FDA actually recalled specific metformin ER products — something that did not occur with Zantac, where the FDA only withdrew approval. An actual recall creates stronger documentary evidence of a defective product reaching consumers.
What Personal Injury Plaintiffs Must Establish
To qualify for the personal injury track of a metformin lawsuit, attorneys are generally evaluating cases that include all of the following elements:
- Metformin ER use — specifically an extended-release formulation from a recalled manufacturer or lot number
- Duration of use of one year or longer — chronic exposure is central to causation arguments
- A qualifying cancer diagnosis — one of the NDMA-associated cancers confirmed by a treating physician
- Documentary evidence — pharmacy records, insurance explanation of benefits (EOB) statements, and prescription refill histories are all critical supporting documents
Estimated compensation tiers in analogous NDMA personal injury cases range from $10,000 for minor injuries to $500,000 or more for severe cancer diagnoses, transplant cases, or wrongful death claims, based on benchmarks from comparable NDMA pharmaceutical litigation. To explore how defective drug injuries are valued in mass tort contexts, the medical malpractice calculator at this site offers a useful analytical framework for early-stage case evaluation.
The Key Defense Argument: FDA Sentinel Data
Defendants in the personal injury track are expected to rely heavily on FDA Sentinel active surveillance data covering 5.4 million metformin users, which showed no statistically detectable cancer signal at the NDMA levels found in recalled products. This data will almost certainly be the centerpiece of a Daubert motion challenging plaintiff expert testimony on general causation. Plaintiffs’ attorneys will counter that population-level surveillance data cannot rule out individual causation, particularly for long-duration, high-exposure users — the same argument that succeeded in early-phase Zantac litigation before the evidentiary battles shifted. This is a genuinely contested scientific question, and mass tort outcomes will depend heavily on which side’s experts survive Daubert scrutiny as MDL consolidation progresses.
Two Tracks, Two Strategies: How to Decide What to Do Right Now
With 11 days until the July 10, 2026 deadline, the decision tree for metformin users is relatively straightforward. If you purchased qualifying metformin ER products during the class period and you do not have a cancer diagnosis linked to NDMA, filing the class action claim costs you nothing and preserves your right to whatever pro-rata payment the settlement generates — expected to be modest but certain. If you do have a cancer diagnosis potentially linked to long-term metformin ER use, the calculus is more complex: staying in the class action releases claims against Teva, Granules, and Heritage for contamination-related conduct, but does not affect your personal injury claims (which the settlement explicitly excludes). Cancer claimants considering individual personal injury cases should consult with a mass tort attorney about whether opting out is strategically advantageous before the July 10 deadline.
For those assessing potential personal injury values across the full spectrum of mass tort claims — not just metformin — a personal injury settlement calculator can help frame the general compensation landscape before engaging formal legal representation.
Frequently Asked Questions: Metformin Lawsuit 2026
Can I file both the class action claim and a personal injury lawsuit?
In most circumstances, yes — but with an important caveat. The class action settlement explicitly excludes personal injury and wrongful death claims, meaning filing a class action claim does not automatically bar a separate cancer-related lawsuit. However, by remaining in the class action and accepting the settlement, you release false-advertising and contamination claims against Teva, Granules/Avet, and Heritage. Cancer victims should discuss with a mass tort attorney whether opting out of the class action before the July 10, 2026 deadline better preserves their legal position for a personal injury case.
Does the metformin class action apply to immediate-release metformin?
No. The FDA’s recall actions — and by extension, this litigation — apply exclusively to extended-release (ER) metformin formulations. The FDA’s own testing found no NDMA contamination in immediate-release metformin products, and no immediate-release products were included in the 2020–2022 recall waves. If you only took immediate-release metformin, you are not part of the class and likely do not have a qualifying claim under either track of the metformin lawsuit.
What documentation do I need to file the class action claim?
Individual consumers are not required to submit documentation to file a claim in the $5.55 million class action settlement. The filing process is designed for ease of access. However, if you are simultaneously preserving evidence for a potential personal injury claim, you should begin gathering pharmacy records, insurance explanation of benefits (EOB) documents, and prescription refill histories now, as these will be essential to any separate cancer-related lawsuit against metformin manufacturers.
How much will class action claimants actually receive?
The payment is distributed on a pro-rata basis across all valid claimants, so the individual amount depends entirely on total claim volume. With a $5.55 million fund and metformin being one of the most widely prescribed diabetes medications in the U.S. — meaning a large potential claimant pool — individual payments may be modest. The fairness hearing on August 12, 2026 will provide further guidance on distribution. Personal injury claimants, by contrast, are looking at estimated ranges of $10,000 to $500,000 or more based on cancer severity, duration of use, and manufacturer liability exposure.
Is there a certified MDL for metformin cancer lawsuits in 2026?
As of mid-2026, no federal multidistrict litigation (MDL) has been formally certified for metformin personal injury cases, though consolidation discussions are actively ongoing and individual cases are accumulating in federal courts. The litigation trajectory is being closely compared to the Zantac NDMA mass tort, with a key distinction: the FDA actually recalled specific metformin ER products, which strengthens plaintiffs’ evidentiary position on product defect. Attorneys expect formal MDL consolidation petitions to be filed later in 2026 as the case inventory grows.
This article is provided for general informational purposes only and does not constitute legal advice; consult a licensed attorney in your jurisdiction for guidance specific to your situation.
Related reading: $22.5 Million Verdict: How Employer Wrongful Death Liability Is Calculated When A Workplace Decision Causes A Death
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.